ATE442850T1 - Kappa-opioid-rezeptor-liganden - Google Patents

Kappa-opioid-rezeptor-liganden

Info

Publication number: ATE442850T1
Authority: AT; Austria
Prior art keywords: opioid receptor; kappa opioid; receptor ligands; antagonists; kappa
Prior art date: 2001-02-01

Application number

AT02704144T

Other languages

English (en)

Inventor

F Carroll

James Thomas

S Mascarella

Original Assignee

Res Triangle Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-01

Filing date

2002-02-01

Publication date

2009-10-15

2002-02-01 Application filed by Res Triangle Inst filed Critical Res Triangle Inst

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE442850T1 publication Critical patent/ATE442850T1/de

Links

102000048260 kappa Opioid Receptors Human genes 0.000 title abstract 3
108020001588 κ-opioid receptors Proteins 0.000 title abstract 3
239000003446 ligand Substances 0.000 title 1
206010013663 drug dependence Diseases 0.000 abstract 2
208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
208000003698 Heroin Dependence Diseases 0.000 abstract 1
229940123257 Opioid receptor antagonist Drugs 0.000 abstract 1
230000001668 ameliorated effect Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
201000006145 cocaine dependence Diseases 0.000 abstract 1
229960002069 diamorphine Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

AT02704144T 2001-02-01 2002-02-01 Kappa-opioid-rezeptor-liganden ATE442850T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/774,566 US6559159B2 (en)	2001-02-01	2001-02-01	Kappa opioid receptor ligands
PCT/US2002/001231 WO2002060445A1 (en)	2001-02-01	2002-02-01	Kappa opioid receptor ligands

Publications (1)

Publication Number	Publication Date
ATE442850T1 true ATE442850T1 (de)	2009-10-15

Family

ID=25101637

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02704144T ATE442850T1 (de)	2001-02-01	2002-02-01	Kappa-opioid-rezeptor-liganden

Country Status (9)

Country	Link
US (1)	US6559159B2 (de)
EP (1)	EP1363629B1 (de)
JP (1)	JP4275945B2 (de)
AT (1)	ATE442850T1 (de)
AU (1)	AU2002237844B2 (de)
CA (1)	CA2436409C (de)
DE (1)	DE60233720D1 (de)
ES (1)	ES2330727T3 (de)
WO (1)	WO2002060445A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7189737B2 (en) *	1991-08-09	2007-03-13	Research Triangle Institute	Cocaine receptor binding ligands
US6538010B1 (en) *	2000-11-08	2003-03-25	Research Triangle Institute	Compounds and methods for promoting smoking cessation
US20030068375A1 (en)	2001-08-06	2003-04-10	Curtis Wright	Pharmaceutical formulation containing gelling agent
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
US7056930B2 (en) *	2003-04-14	2006-06-06	Pfizer Inc.	2-Azabicyclo[3.3.1]nonane derivatives
US7201920B2 (en) *	2003-11-26	2007-04-10	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of opioid containing dosage forms
CA2916869A1 (en)	2004-06-12	2005-12-29	Jane C. Hirsh	Abuse-deterrent drug formulations
US20080045610A1 (en) *	2004-09-23	2008-02-21	Alexander Michalow	Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) *	2004-09-23	2008-05-08	ミシャロウ、アレクサンダー	対抗適応を誘発することにより神経伝達物質系を調節する方法
US20080152595A1 (en) *	2004-11-24	2008-06-26	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) *	2004-11-24	2007-10-04	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) *	2004-11-24	2006-08-10	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) *	2004-11-24	2006-05-25	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US7872023B2 (en) *	2005-02-17	2011-01-18	Research Triangle Institute	Kappa opioid receptor ligands
US7399762B2 (en) *	2005-04-25	2008-07-15	Research Triangle Institute	Opioid receptor agonist compounds and their use in treatment of pain
US7476679B2 (en) *	2005-07-26	2009-01-13	Research Triangle Institute	Octahydroisoquinoline compounds as opioid receptor modulators
EP2258358A3 (de)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US8329744B2 (en) *	2005-11-02	2012-12-11	Relmada Therapeutics, Inc.	Methods of preventing the serotonin syndrome and compositions for use thereof
WO2007056142A2 (en) *	2005-11-02	2007-05-18	Theraquest Biosciences, Llc	Methods of preventing the serotonin syndrome and compositions for use therefor
US20090082466A1 (en) *	2006-01-27	2009-03-26	Najib Babul	Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US9125833B2 (en) *	2005-11-02	2015-09-08	Relmada Therapeutics, Inc.	Multimodal abuse resistant and extended release opioid formulations
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
EP2382975A3 (de)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenese mittels Angiotensin-Modulation
AU2007292848A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
JP2011500686A (ja) *	2007-10-18	2011-01-06	アイコバイオテクノロジー	オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
US8748448B2 (en)	2007-10-18	2014-06-10	Aiko Biotechnology	Combination analgesic employing opioid agonist and neutral antagonist
US8048895B2 (en) *	2008-04-18	2011-11-01	Research Triangle Institute	Kappa opioid receptor ligands
CA2727573A1 (en) *	2008-06-25	2009-12-30	Pfizer Inc.	Diaryl compounds and uses thereof
RU2673882C1 (ru)	2008-10-30	2018-12-03	Грюненталь Гмбх	Новые и эффективные лекарственные формы тапентадола
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
AU2010300641B2 (en) *	2009-09-30	2016-03-17	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse
US10668060B2 (en)	2009-12-10	2020-06-02	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2539706B1 (de)	2010-02-24	2015-03-04	Research Triangle Institute	Arylpiperazin-opioid-rezeptor-antagonisten
ME02874B (de)	2010-12-22	2018-04-20	Purdue Pharma Lp	Gekapselte manipulationssichere Darreichungsformen mit gesteuerter Freisetzung
PH12013501345A1 (en)	2010-12-23	2022-10-24	Purdue Pharma Lp	Tamper resistant solid oral dosage forms
MX366159B (es)	2012-11-30	2019-07-01	Acura Pharmaceuticals Inc	Liberacion autorregulada de ingrediente farmaceutico activo.
US9283196B1 (en)	2013-01-30	2016-03-15	MediSynergics, LLC	Cycloalkyl-diamines for CNS disorders
MX2015010041A (es)	2013-02-05	2015-10-30	Purdue Pharma Lp	Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en)	2013-03-15	2020-08-25	Purdue Pharma L.P.	Tamper resistant pharmaceutical formulations
WO2015145461A1 (en)	2014-03-26	2015-10-01	Sun Pharma Advanced Research Company Ltd.	Abuse deterrent immediate release biphasic matrix solid dosage form
US11103581B2 (en)	2015-08-31	2021-08-31	Acura Pharmaceuticals, Inc.	Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9737530B1 (en)	2016-06-23	2017-08-22	Collegium Pharmaceutical, Inc.	Process of making stable abuse-deterrent oral formulations
JP2021505671A (ja) *	2017-12-08	2021-02-18	ザロックフェラーユニバーシティＴｈｅＲｏｃｋｅｆｅｌｌｅｒＵｎｉｖｅｒｓｉｔｙ	中毒症、掻痒症、疼痛および炎症治療用ピラノ［３，４−ｂ］ピラジンカッパオピオイド受容体リガンド
WO2019182950A1 (en) *	2018-03-19	2019-09-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4278797A (en)	1979-03-12	1981-07-14	Eli Lilly And Company	Intermediates to phenylmorphans and method of preparation thereof

2001
- 2001-02-01 US US09/774,566 patent/US6559159B2/en not_active Expired - Fee Related
2002
- 2002-02-01 AT AT02704144T patent/ATE442850T1/de not_active IP Right Cessation
- 2002-02-01 DE DE60233720T patent/DE60233720D1/de not_active Expired - Lifetime
- 2002-02-01 CA CA2436409A patent/CA2436409C/en not_active Expired - Fee Related
- 2002-02-01 JP JP2002560637A patent/JP4275945B2/ja not_active Expired - Fee Related
- 2002-02-01 AU AU2002237844A patent/AU2002237844B2/en not_active Ceased
- 2002-02-01 EP EP02704144A patent/EP1363629B1/de not_active Expired - Lifetime
- 2002-02-01 ES ES02704144T patent/ES2330727T3/es not_active Expired - Lifetime
- 2002-02-01 WO PCT/US2002/001231 patent/WO2002060445A1/en not_active Ceased

Also Published As

Publication number	Publication date
CA2436409A1 (en)	2002-08-08
JP2004520383A (ja)	2004-07-08
ES2330727T3 (es)	2009-12-15
WO2002060445A1 (en)	2002-08-08
US6559159B2 (en)	2003-05-06
EP1363629A1 (de)	2003-11-26
AU2002237844B2 (en)	2006-03-16
JP4275945B2 (ja)	2009-06-10
US20020143145A1 (en)	2002-10-03
EP1363629A4 (de)	2004-03-31
EP1363629B1 (de)	2009-09-16
DE60233720D1 (de)	2009-10-29
CA2436409C (en)	2010-12-07

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60233720D1 (de)	2009-10-29	Kappa-opioid-rezeptor-liganden
ATE389404T1 (de)	2008-04-15	Kappa-opioid-rezeptor-liganden
AU2003299747A8 (en)	2004-07-22	Tumor killing/tumor regression using cxcr4 antagonists
SI1957539T1 (sl)	2013-05-31	Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba
AP2004002982A0 (en)	2004-03-31	Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
EP1827468A4 (de)	2009-08-05	Leuprolidacetat und acetylcholinesterase-hemmer oder nmda-rezeptorantagonisten zur behandlung von alzheimer-krankheit
MXPA03008739A (es)	2003-12-11	Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
EP1983002A3 (de)	2009-03-11	Tyrosinphosphorylations-Stellen und spezifische Antikörper
WO2008013954A3 (en)	2008-10-16	Tyrosine phosphorylation sites
WO2008054597A3 (en)	2008-10-09	Tyrosine phosphorylation sites
DE50011178D1 (de)	2005-10-20	Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
MX233159B (es)	2005-12-19	Composiciones para tratamientos de telas.
DE60324431D1 (de)	2008-12-11	Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
WO2008013934A8 (en)	2008-03-13	Tyrosine phosphorylation sites
ZA200307475B (en)	2005-01-03	Carbamate compounds for use in the treatment of pain.
IL139217A0 (en)	2001-11-25	Monoclonal antibodies to the human ldl receptor, their production and use
HUP0300339A3 (en)	2009-01-28	Use of fulvestrant in the treatment of resistant breast cancer
ATE556071T1 (de)	2012-05-15	Kappa-opioidrezeptor-liganden
EP1782944A4 (de)	2010-05-05	Hammer und drehformpressmaschine damit
MXPA05011699A (es)	2006-01-23	Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
ZA200501288B (en)	2005-09-05	Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
EP2292666A3 (de)	2011-06-08	Neoplasma-spezifische Antikörper und deren Verwendungen
PL369402A1 (en)	2005-04-18	Use for the treatment of gastroesophageal reflux disease
NO20030593D0 (no)	2003-02-06	Fremgangsmåter for behandling av cancer og smerten forbundet derved ved å anvende endotelinantagonister
WO2004081027A3 (en)	2005-03-10	Neoplasm specific antibodies and uses thereof